Pioneering studies in the late 1990s and early 2000s initially reported successful treatment of adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and other hematological disorders (56–59); however, these successes were soon overshadowed by reports of patients who experienced significant adverse events including the development of treatment-related leukemias and severe immune reactions (60–65). The gene discussed is ADA; the disease is hematologic disorder.